Bristol-Myers and Starboard Value spar over $74B Celgene buyout as shareholder vote looms
Bristol-Myers Squibb execs and Starboard Value are back at it today, exchanging broadsides for and against the $74 billion buyout.
There’s not much fresh material to pick over at this point. Bristol-Myers CEO Giovanni Caforio has been trying to bat back every criticism that Starboard and its allies have raised.
Image: Giovanni Caforio. AP IMAGES
Depending on who you listen to here, Bristol-Myers either:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
